Consistent with the hepatocyte-specific JNK deletion model, Elafibranor (GFT505, Genfit), a PPARα/β agonist, Saroglitazar, a PPARα/γ agonist, and lanifibranor, a pan-PPAR agonist normalize serum lipid profiles, insulin resistance and improve NASH [121]. This evidence concerns the gene MAPK8 and metabolic dysfunction-associated steatohepatitis.